CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”
T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells to recognize and get attached to an antigen (specific protein) on the tumor cell leading to the destruction of the tumor.
Since the approval of the first CAR-T cell therapeutic in 2017, widespread research, an exponential increase in clinical trial activity, proliferative M&A activity, and lucrative IPOs have created a robust CAR-T cell market. This billion dollar market would not have been possible without the remarkable efficacy of Kymriah, Yescarta, and Tecartus in treating several types of blood cancers.
CAR-T Cell Therapy Market
In 2012, there were only 12 clinical trials investing CAR-T cell therapy products. Today, that number has risen to 514. Between 2017 and 2020, three CAR-T products reached the market, and this number is projected to reach double digits by 2024. The earliest approvals, Kymriah and Yescarta, have been commercially available since 2017 and 2018, respectively, and have been infused into nearly a half million patients worldwide. In July 2020, the U.S. FDA approved a third CAR-T cell therapy, Kite Pharma’s brexucabtagene autoleucel (sold as Tecartus).
All the three of the approved CAR-T products and nearly 75% of the ongoing clinical trials take an autologous treatment approach. Autologous (self-derived) CAR-T cells are expensive to produce because they are manufactured on a patient-by-patient basis. At times, autologous production can be hampered by a shortage of CAR-T cells or viral vectors. The cost of autologous CAR-T therapy is further escalated by the need for a complex cold chain during transportation. Another key issue is the “vein-to-vein” time or the time that elapses between apheresis and product delivery.
Thus, CAR-T therapies are most often recommended for end-stage patients who have exhausted all the other treatment options. These challenges drive up the price, making CAR-T therapy unaffordable for a large percentage of patients.
To support the adoption of CAR-T cell therapies, the industry is taking measures to mitigate these challenges. Several CAR-T players have started using efficient gene-transfer tools to impregnate the T cells with CARs. There are numerous examples of partnerships to develop CRISPR and electroporation technologies to modify T cells. Some companies are also using “on-off” switches that can turn off CAR-T cells to prevent toxicity.
Unfortunately, the goal of achieving CAR-T success against solid tumors remains elusive thus far, with clinical trials demonstrating a severely limited response.
Trends in CAR-T Cell Therapy
CAR-T cell therapy has taken the biotech industry by storm, creating hope that it could usher in a new era of cancer treatment. However, the success stories have come from targeting CD19, which is now considered an antigen that holds the key to a limited range of blood cancers. Presently, this hematological arena is highly competitive and is being targeted by numerous CAR-T cell therapy competitors.
Scientists, investors and developers invariably agree that the key to longer-term success in this sector depends on solving two major problems: identifying antigens other than CD19 that can be targeted with CAR-T therapy with strong efficacy and going beyond liquid cancers into solid tumor indications. CAR-T cell products targeted against solid tumors will undoubtedly offer a larger market potential.
However, it is not an easy task to identify the antigens found on the cells of solid tumors. There are reasons why CD19 is the most common target. It is seen solely on B cells, whose destruction via CAR-T therapy offers a straightforward route for treating B-cell leukemias and lymphomas. At the same time, loss of the body’s B cells is not particularly problematic, because their antibody-producing function can be reinstated by injecting intravenous immunoglobulin (IVIG) to patients.
Driving Forces Impacting the CAR-T Cell Therapy Market
2017 was the first year that the U.S. FDA approved a CAR-T cell therapy, approving Kymriah in August 2017 and Yescarta in October 2017. Novartis produced Kymriah, a CAR-T therapy used to treat leukemia, while Gilead/Kite Pharma produced Yescarta, a CAR-T therapy to designed for patients with lymphoma. Approvals for these products spread like wildfire, with the EU, Canada, Australia, Japan, and other nations following suit.
In July 2020, the U.S. FDA approved the third CAR-T cell therapy, approving Kite Pharma’s brexucabtagene autoleucel, sold as Tecartus. It is the first CAR-T therapeutic to treat relapsed or refractory mantle cell lymphoma (MCL). The approval of these early CAR-T cell therapies has opened the gates for many other types of cell and gene therapies to claim respect, from regulators, as well as the scientific and medical community at large.
Today, the CAR-T cell therapy industry is witnessing:
- Landmark approvals of CAR-T cell therapies by regulatory bodies worldwide
- Lucrative acquisitions within the CAR-T industry
- Large IPOs within the industry
- An increasingly competitive IP environment
- Unprecedented investment flowing into CAR-T cell research
CAR-T cell therapy has proven a promising new treatment approach. As its manufacture, administration, and safety profile improve, we will usher in a new era of CAR-T cell therapeutics.
This global strategic report reveals:
- Market size determinations with segmentation and forecasts through 2027
- Approved CAR-T products by indication and region
- Clinical trial activity by type, region, phase, and sponsor
- CAR-T industry M&A transactions and IPOs
- Strategic partnerships and commercialization agreements
- Industry trends and future directions
- Competitors composing the global marketplace
This 232-page global strategic report will position you to:
- Capitalize on emerging trends
- Improve internal decision-making
- Reduce company risk
- Approach outside partners and investors
- Outcompete your competition
- Implement an informed and advantageous business strategy in 2021
With the competitive nature of this global market, you don’t have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities.
1. Report Overview
1.1 Statement of the Report
1.2 Executive Summary
2. Chimeric Antigen Receptor-T (Car-T) Cell Therapy: A Brief Overview
2.1 CAR-T Cell
2.2 Evolution of CAR-T Cell Development
2.2.1 The CAR-T Cell Family
126.96.36.199 First Generation CARs
188.8.131.52 Second Generation CARs
184.108.40.206 Third Generation CARs
220.127.116.11 Fourth Generation CARs
2.3 Antigens Present on Hematological Cancer Cells
2.4 Tools for Inserting Receptor Genes into T Cells
2.5 Transforming T Cells into CAR-T Cells
2.6 The Three CAR-T Therapies Crossing the Finishing Line
2.7 Toxicities Associated with CAR-T Treatment
2.8 The Future of CAR-T Cell Therapy
2.8.1 Transition from Liquid Cancers to Solid Tumors
2.8.2 Reduction in the Length of Hospital Stay
2.8.3 Discovery of New Target Antigens
2.8.4 Shifting from Autologous to Allogeneic CAR-T Therapy
2.8.5 CAR-T for the Masses
2.9 Advantages of CAR-T Therapy
2.10 Disadvantages of CAR-T Therapy
3. History of CAR-T Cell Therapy
3.1 Current Status of CAR-T Therapy Products
3.2 Prospective CAR-T Product Candidates
3.3 Transformative Potential of CAR-T Therapy
3.4 Small Patient Population & Huge Clinical Trial Landscape
4. Manufacture of CAR-T Cells
4.1 Automation in CAR-T Manufacturing
4.2 Operating Expenses in Autologous CAR-T Manufacturing
4.3 Operating Expenses in Allogeneic CAR-T Manufacturing
5. CAR-T Target Antigens: A Brief Overview
5.1 CAR-T Target Antigens on Hematological Cancers
5.2 CAR-T Target Antigens on Solid Tumors
5.3 Common Antigens Targeted by CAR-T Cells
5.3.1 Cluster of Differentiation 19 (CD19)
5.3.3 B-Cell Maturation Agent (BCMA)
5.3.5 Glypican-3 (GPC3)
5.3.6 Cluster Differentiation-22 (CD22)
6. CAR-T Patent Landscape
6.1 Geographical Origin of CAR-T Patent Applications
6.2 Top Ten CAR-T Patent Jurisdictions
6.3 Affiliations of CAR-T Cell Patent Applicants
6.3.1 Top 20 Companies in CAR-T Patent Landscape
6.3.2 TOP 20 Research Centers in CAR-T Patent Landscape
6.3.3 Top 20 CAR-T Cell Inventors
6.3.4 Top Five CAR-T Patents with Most Family Members
6.3.5 Top Five CAR-T Patents with Most Inventors in Co-Authorship
6.3.6 Top Five Patents with Most Co-Applicants
6.3.7 Top Five CAR-T Patents with Most Citations Received
7. Global CAR-T Clinical Trials: An Overview
7.1 CAR-T Targeted Biomarkers in Clinical Trials
7.1.1 CAR-T Targeted Biomarkers in U.S. Clinical Trials
7.1.2 CAR-T Targeted Biomarkers in Chinese Clinical Trials
7.1.3 CAR-T Targeted Biomarkers in other Countries
7.2 CAR-T Targeted Indications in the U.S. Clinical Trials
7.3 Indications Addressed by CAR-T Clinical Trials in China
7.4 Percent Share of Indications Addressed by the Ongoing CAR-T Clinical Trials
7.5 Phase of CAR-T Clinical Trials
7.6 CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S.
7.7 CAR-T Clinical Trial Sponsor Companies and Institutions in China
7.8 CAR-T Clinical Trial Sponsor Companies and Institutions in other Countries
7.9 Ongoing Clinical Trials with Improved CAR-T Constructs
7.9.1 CAR-T with PD1Fc
7.9.2 CAR-T with Truncated EGFR (EGFRt)
7.9.3 CAR-T with IL7 and CCL19
7.9.4 CAR-T with PD1/CD28 Switch-Receptor
7.9.5 CAR-T with PD1 shRNA-expressing cassette
7.9.6 CAR-T with CTLA-4/PD-1 Antibody
7.9.7 CAR-T with PD-1 Antibodies
7.10 Geographic Distribution of CAR-T Clinical Trials
7.11 Distribution of CAR-T Clinical Trials by Type of CAR Generations
7.12 Distribution of CAR-T Clinical Trials by Type of ScFv Used
7.13 Distribution of CAR-T Clinical Trials by Type of Vectors Used
8. Published Scientific Papers & NIH Grants
8.1 Number of Published Papers
8.2 NIH Funding for CAR-T Research
9. Deals in CAR-T Therapy Space
9.1 Most Recent CAR-T Deals
9.1.1 Gilead Sciences/Tango Therapeutics
9.1.4 Juno/Oxford Biomedica
9.1.6 Applied DNA Sciences, Inc.
9.1.8 Cell Therapies, Pvt. Ltd
9.1.11 Carisma Therapeutics, Inc./NYU Langone Health
10. Marketed CAR-T Products
10.1 Kymriah (Tisagenlecleucel)
10.1.1 Mechanism of Action
10.1.3 Safety and Efficacy of Kymriah
10.1.4 Kymriah’s Cost
10.1.5 Current Sales of Kymriah
10.2 Yescarta (Axicabtagene ciloleucel)
10.2.1 Mechanism of Action
10.2.4 Safety and Efficacy of Yescarta
10.2.5 Manufacturing Network
10.2.6 Current sales of Yescarta
10.2.7 Sales of Kymriah and Yescarta: A Comparison
10.3 Tecartus (Brexucabtagene autoleucel)
10.3.1 Mechanism of Action
10.3.3 Safety and Efficacy of Tecartus
10.3.4 Efficacy, Safety and Composition of Approved CAR-T Products
10.4 Other Promising CAR-T Product Candidates
10.4.1 Liso-Cel (Lisocabtagene Maraleucel)
10.4.2 0Idecabtagene Vicleucel (Ide-cel, bb2121)
11. Reimbursement for Car-T Therapies
11.1 Hospital Reimbursement in the U.S. for CAR-T Therapy
11.2 Outcomes-Based Reimbursement for CAR-T Therapies in EU5 Countries
12. Blood Cancers: An Overview
12.1.1 Hodgkin Lymphoma (HL)
12.1.2 Non-Hodgkin Lymphoma (NHL)
18.104.22.168 Diffuse Large B Cell Lymphoma (DLBCL)
22.214.171.124 Follicular Lymphoma (FL)
12.2.1 Types of Leukemia
126.96.36.199 Acute Myeloid Leukemia (AML)
188.8.131.52 Acute Lymphoblastic Leukemia (ALL)
184.108.40.206 Chronic Myeloid Leukemia (CML)
220.127.116.11 Chronic Lymphocytic Leukemia (CLL)
12.3 Multiple Myeloma (MM)
12.4 Treatment Options for Blood Cancers
12.4.2 Radiation Therapy
12.4.3 Targeted Therapy
12.4.4 Stem Cell Transplantation
18.104.22.168 Monoclonal Antibodies (mAbs)
22.214.171.124 Immune Check-point Inhibitors
126.96.36.199 Adoptive Cell Transfer Therapy/T-Cell Transfer Therapy
12.5 The Staggering Cost of Cancer Therapy
13. Market Analysis
13.1 Global Market for CAR-T Cell Therapy by Product
13.2 Global CAR-T Market by Geography
13.3 Global Market for CAR-T Therapy by Indication
13.4 Companies at the Forefront of CAR-T Market
13.5 Barriers and Strategies for Success in CAR-T 2.0 Market Place
13.5.1 Barriers to CAR-T 2.0 Commercial Success
188.8.131.52 Capacity constraints
184.108.40.206 Competition among Manufacturers
220.127.116.11 Competition from other Treatments
13.5.2 Market Development Strategies for CAR-T 2.0
18.104.22.168 Effective Physician Education
22.214.171.124 Logistical Excellence
126.96.36.199 Evidence Generation
14. Company Profiles
14.1 Aleta BioTherapeutics
14.1.1 Atela’s Pipeline
14.2 Allogene Therapeutics
14.2.1 AlloCAR-T Therapy
14.3 Anixa Biosciences, Inc.
14.4 Attars Biotherapeutics
14.4.2 Next-Generation CAR-T
14.5 Autolus Therapeutics, plc
14.6 Bellicum Pharmaceuticals, Inc.
14.6.1 GoCAR Technology
14.6.2 Bellicum’s Pipeline
14.7.3 Engineered Cell Therapies
14.7.4 CAR-T Programs
14.8 bluebird bio
14.8.1 CAR-T Collaborations
188.8.131.52 Collaboration with Celgene
184.108.40.206 Collaboration with Inhibrx
220.127.116.11 Collaboration with TC BioPharm
14.9 Carina Biotech
14.9.1 New CAR-T Cells
14.9.2 CAR-T Access Technologies
18.104.22.168 Chemokine Receptor Mediation
22.214.171.124 Gel Formulation to Deliver CAR-T Cells
14.10 CARsgen Therapeutics
14.11 Cartesian Therapeutics, Inc.
14.11.1 Cartesian’s Approach
14.13 Celgene Corporation
14.13.1 Lisocabtagene maraleucel (liso-cel)
14.14.1 Universal Chimeric Antigen Receptor T-Cells (UCARTs)
14.15 Celularity, Inc.
14.15.1 P CAR-T
14.16 Celyad Oncology
14.16.1 TIM Technology
14.16.2 shRNA Technology
14.17 Creative Biolabs
14.17.1 CAR Construction and Production Platform
14.18 CRISPR Therapeutics
14.18.1 CRISPR/Cas9 Immuno-Oncology Cell Therapy
14.19 Cytovia Therapeutics
14.20 DiaCarta, Inc.
14.20.1 Personalized CAR-T Immunotherapy Platform
14.21 Empirica Therapeutics
14.22 Eureka Therapeutics, Inc.
14.23 EXUMA Biotech Corp.
14.23.1 Logic Gate CAR-T Technology
14.23.2 Same-Day CAR-T Therapy
14.24 Fate Therapeutics, Inc.
14.25 Formula Pharmaceuticals, Inc.
14.26 Gilead Sciences, Inc.
14.26.1 TECARTUS (Brexucabtagene autoleucel)
14.26.2 Yescarta (Axicabtagene ciloleucel)
14.26.3 Cell Therapy
14.27 Gracell Biotechnologies
14.27.1 Dual CAR
14.28 iCell Gene Therapeutics
14.28.1 iCell Platforms
126.96.36.199 Non Gene Edited Universal CARs
188.8.131.52 T-Cell Targeted CARs
184.108.40.206 Compound CARs
14.29 Janssen Biotech, Inc.
14.30 Juno Therapeutics
14.31 JW Therapeutics, Co., Ltd.
14.31.1 Relmacabtagene autoleucel (Relma-cel)
14.32 Kite Pharma, Inc.
14.32.1 Kite’s Technologies (CAR-T & TCR)
14.32.2 Kite’s Therapies
220.127.116.11 Yescarta (Axicabtagene ciloleucel)
18.104.22.168 Tecartus (Brexucabtagene autoleucel)
14.33 MaxCyte, Inc.
14.33.1 CARMA Cell Therapies
14.33.2 Flow Electroporation Technology
14.34 Minerva Biotechnologies Corporation
4.35 Mustang Bio, Inc.
14.36 Nanjing Legend Biotechnology Co., Ltd.
14.37 Noile-Immune Biotech
14.38 Novartis International, AG
14.38.1 Kymriah (Tisagenlecleucel)
14.39 Oxford Biomedica plc
14.40 PeproMene Bio, Inc.
14.40.1 BAFF-R CAR-T Cells
14.41 Poseida Therapeutics, Inc.
14.41.1 PiggyBac DNA Modification System
14.41.2 Autologous & Allogeneic Programs
14.42 Precigen, Inc.
14.43 Precision Biosciences
14.44 Prescient Therapeutics
14.44.1 OmniCAR Technology
14.45 ProMab Biotechnologies, Inc.
14.45.1 Custom CAR-T Cell Development
14.47 Sorrento Therapeutics, Inc.
14.48 TC Biopharm
14.48.1 Co-Stim CAR-T
14.50 Tessa Therapeutics, Pvt. Ltd.
14.50.1 CD30 CAR-T Cells
14.50.2 Allogeneic CD30-CAR EBVSTs
14.51 Tmunity Therapeutics, Inc.
14.53 Xyphos Biosciences, Inc.
14.53.1 Xyphos’ Strategy
14.54 Ziopharm Oncology, Inc.
14.54.1 Non-Viral CAR-T Therapy
Index of Figures
Figure 2.1: The Basic Structure of a T Cell
Figure 2.2: The Binding of T Cells onto an Infected Cell
Figure 2.3: Components of a CAR-T Cell
Figure 2.4: The Three Domains of a CAR
Figure 2.5: First Generation CARs
Figure 2.6: Second Generation CARs
Figure 2.7: Third Generation CARs
Figure 2.8: Fourth Generation CARs
Figure 2.9: Flow Chart Showing the Process of Manufacture of CAR-T Cells
Figure 2.10: Diagrammatic Illustration of Autologous CAR-T
Figure 2.11: Diagrammatic Illustration of Allogeneic CAR-T
Figure 4.1: Leukopheresis and T Cell Isolation
Figure 4.2: T Cell Culture and Transduction
Figure 4.3: The Workflow in an Automated Manufacturing Unit
Figure 4.4: Operating Expenses in Autologous CAR-T Manufacturing
Figure 4.5: Operating Expenses in Allogeneic CAR-T Manufacturing
Figure 5.1: The CAR-T Target Distribution in Global Clinical Trials
Figure 6.1: CAR-T-Related Patent Publications, 2012-2019
Figure 6.2: Granted CAR-T-Related Patents, 2012-2019
Figure 6.3: Geographical Origin of CAR-T Patent Applications
Figure 6.4: Top Ten CAR-T Patent Jurisdictions
Figure 6.5: Affiliations of CAR-T Cell Patent Applicants
Figure 7.1: Number of Clinical Trials per Year, U.S. vs. China, 2003-2019
Figure 7.2: CAR-T Targeted Biomarkers in other Countries
Figure 7.3: Percent Share of Indications Addressed by the Ongoing CAR-T Clinical Trials
Figure 7.4: CAR-T Clinical Trials Phase Summary, U.S. vs. China
Figure 7.5: Geographic Distribution of CAR-T Clinical Trials
Figure 7.6: Distribution of CAR-T Clinical Trials by Type of CAR Generations
Figure 7.7: Distribution of CAR-T Clinical Trials by Type of ScFv Used
Figure 7.8: Distribution of CAR-T Clinical Trials by Type of Vectors Used
Figure 8.1: Number of CAR-T-Related Published Papers in PubMed.gov
Figure 10.1: Sales Revenues for Kymriah, 2018-2020
Figure 10.2: Sales Revenues for Yescarta, 2018-2020
Figure 10.3: Sales Data for Kymriah and Yescarta, Q1 of 2018 to Q2 of 2020
Figure 12.1: Global Incidence of Blood Cancers in 2018
Figure 12.2: Rate of Incidence and Death for Hodgkin Lymphoma in the U.S.
Figure 12.3: Rate of New NHL Cases in the U.S.
Figure 12.4: Rate of New DLBCL Cases in the U.S.
Figure 12.5: Rate of New FL Cases in the U.S.
Figure 12.6: Rate of New Leukemia Cases in the U.S.
Figure 12.7: Distribution of New Leukemia Cases in the U.S. by Type
Figure 12.8: Rate of New AML Cases in the U.S.
Figure 12.9: Rate of New ALL Cases in the U.S.
Figure 12.10: Rate of New CML Cases in the U.S.
Figure 12.11: Rate of New CLL Cases in the U.S.
Figure 12.12: Rate of New MM Cases in the U.S.
Figure 13.1: Estimated Global Market for CAR-T Therapy by Products, 2019-2027
Figure 13.2: Global Market for CAR-T Therapy by Geography, 2019-2027
Figure 13.3: Global Market for CAR-T Therapy by Indication, 2019-2027
Figure 14.1: Illustration of a Dual CAR
Index of Tables
Table 2.1: CAR-Targeted Antigens Present on Hematological Malignancies
Table 2.2: The Three CAR-T Therapies Crossing the Finishing Line: An Overview
Table 2.3: Toxicities Associated with CAR-T Treatment
Table 2.4: Strategies to Improve the Safety and Efficacy of CAR-T Therapy
Table 2.5: New Target Antigens and New Target Cancers
Table 2.6: A Partial List of Allogeneic CAR-T Companies
Table 3.1: History of Development of CAR-T Cells
Table 3.2: Approved CAR-T Products and Indications
Table 3.3: The Next-Wave of CAR-T Approvals
Table 3.4: Increased CAR-T Activity
Table 3.5: Very Small Patient Population Addressed by CAR-T Clinical Trials
Table 5.1: CAR-T Cell Target Antigens for Hematological Malignancies
Table 5.2: CAR-T Target Antigens on Solid Tumors
Table 6.1: Top 20 Companies in CAR-T Patent Landscape
Table 6.2: TOP 20 Research Centers in CAR-T Patent Landscape
Table 6.3: Top 20 CAR-T Inventors
Table 6.4: Top Five CAR-T Patents with Maximum Patent Families
Table 6.5: Top Five CAR-T Patents with Most Inventors in Co-Authorship
Table 6.6: Top Five Patents with Most Co-Applicants
Table 6.7: Top Five Patents with Most Co-Applicants
Table 7.1: Percent Target Distribution of World’s CAR-T Clinical Trials
Table 7.2: Targeted Biomarkers in the U.S. CAR-T Clinical Trials
Table 7.3: Targeted Biomarkers in Chinese CAR-T Clinical Trials
Table 7.4: Indications Addressed by CAR-T Clinical Trials in the U.S.
Table 7.5: Indications Addressed by CAR-T Clinical Trials in China
Table 7.6: CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S.
Table 7.7: CAR-T Clinical Trial Sponsor Companies and Institutions in China
Table 7.8: CAR-T Clinical Trial Sponsor Companies and Institutions in Other Countries
Table 7.9: Clinical Trials of Fourth Generation/Next-Generation and Gene-Edited CAR-T
Table 8.1: A Partial List of NIH Funding for CAR-T Research in 2020
Table 9.1: Deals in CAR-T Therapy Space, 2012-2019
Table 10.1: Sales Data for Kymriah and Yescarta, 2018 Full Year to 2020 Mid-Year
Table 10.2: Efficacy, Safety and Composition of Approved CAR-T Products
Table 10.3: Other Promising CAR-T Product Candidates
Table 11.1: 2020 CAR-T Payment Disparities per Case in the U.S.
Table 11.2: Reimbursement of CAR-T Cell Therapies in France
Table 11.3: Reimbursement of CAR-T Cell Therapies in Germany
Table 11.4: Reimbursement of CAR-T Cell Therapies in Italy
Table 11.5: Reimbursement of CAR-T Cell Therapies in Spain
Table 11.6: Reimbursement of CAR-T Cell Therapies in U.K.
Table 12.1: Cost of Treating Blood Cancers
Table 13.1: Estimated Global Market for CAR-T Therapy by Products, 2019-2027
Table 13.2: Global Market for CAR-T Therapy by Geography, 2019-2027
Table 13.3: Global Market for CAR-T Therapy by Indication, 2019-2027
Table 13.4: Top Five CAR-T Companies by Marketed Products and Product Candidates
Table 14.1: Atela’s Pipeline of Product Candidates
Table 14.2: Allogene’s Product Pipeline
Table 14.3: Anixa’s Product Pipeline
Table 14.4: Autolus’ Pipeline of Clinical and Next Generation Programs
Table 14.5: Bellicum Pharmaceutical’s Product Candidates
Table 14.6: CARsgen’s Product Pipeline
Table 14.7: Cartesian’s Product Pipeline
Table 14.8: Celyad’s Product Pipeline
Table 14.9: Creative Biolab’s CAR Construction and Production Platform
Table 14.10: CRISPR Therapeutics’ Immuno-Oncology Programs
Table 14.11: Cartesian’s Product Pipeline
Table 14.12: Eureka’s CAR Products in Development for Juno Therapeutics
Table 14.13: iPSC-Derived Product Candidates from Fate Therapeutics
Table 14.14: Formula’s Product Candidates
Table 14.15: Gilead’s Cell Therapy Programs in Oncology
Table 14.16: iCell’s Product Candidates
Table 14.17: Juno’s CAR-T Product Candidates
Table 14.18: Kite’s Pipeline of Product Candidates
Table 14.19: Mustang Bio’s Product Candidates
Table 14.20: Nanjing’s Autologous Product Pipeline for Hematologic Malignancies
Table 14.21: Nanjing’s Allogeneic Product Pipeline for Hematologic and Solid Cancers
Table 14.22: Noil’s Product Candidates for Solid Cancers
Table 14.23: Oxford Biomedica’s IP Enabled and Royalty Bearing Product Candidates
Table 14.24: Poseida’s Product Pipeline
Table 14.25: Precigen’s CAR-T Programs
Table 14.26: Precision Bioscience’s Off-the-Shelf Immunotherapy Pipeline
Table 14.27: Sorrento’s Immunotherapy Pipeline
Table 14.28: TC Biopharm’s Product Candidates
Table 14.29: Tmunity’s CAR-T Programs for Liquid and Solid Tumors
Table 14.30: Wugen’s Pipeline of Product Candidates
Table 14.31: Xyphos’ Product Pipeline
Table 14.32: Ziopharm’s CAR-T Product Candidates
- Aleta BioTherapeutics
- Allogene Therapeutics
- Anixa Biosciences, Inc.
- Attars Biotherapeutics
- Autolus Therapeutics, plc
- Bellicum Pharmaceuticals, Inc.
- bluebird bio
- Carina Biotech
- CARsgen Therapeutics
- Cartesian Therapeutics, Inc.
- Celgene Corporation
- Celularity, Inc.
- Celyad Oncology
- Creative Biolabs
- CRISPR Therapeutics
- Cytovia Therapeutics
- DiaCarta, Inc.
- Empirica Therapeutics
- Eureka Therapeutics, Inc.
- EXUMA Biotech Corp.
- Fate Therapeutics, Inc.
- Formula Pharmaceuticals, Inc.
- Gilead Sciences, Inc.
- Gracell Biotechnologies
- iCell Gene Therapeutics
- Janssen Biotech, Inc.
- Juno Therapeutics
- JW Therapeutics, Co., Ltd.
- Kite Pharma, Inc.
- MaxCyte, Inc.
- Minerva Biotechnologies Corporation
- Mustang Bio, Inc.
- Nanjing Legend Biotechnology Co., Ltd.
- Noile-Immune Biotech
- Novartis International, AG
- Oxford Biomedica plc
- PeproMene Bio, Inc.
- Poseida Therapeutics, Inc.
- Precigen, Inc.
- Precision Biosciences
- Prescient Therapeutics
- ProMab Biotechnologies, Inc.
- Sorrento Therapeutics, Inc.
- TC Biopharm
- Tessa Therapeutics, Pvt. Ltd.
- Tmunity Therapeutics, Inc.
- Xyphos Biosciences, Inc.
- Ziopharm Oncology, Inc.
The content and statistics contained within the publisher's reports are compiled using a broad range of sources, as described below.
- Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register, Chinese Clinical Trial Registry, Others)
- Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
- Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization, Google Patent Search)
- Grant Funding Databases (RePORT Database, CIRM, MRC, Wellcome Trust - UK, Others)
- Product Launch Announcements (Trade Journals, Google News)
- Industry Events (Google News, Google Alerts, Press Releases)
- Company News (SEC Filings, Investor Publications, Historical Performance)
- Social Analytics (Google Adwords, Google Trends, Twitter, Topsy.com, Hashtagify.me, BuzzSumo.com)
- Interviews with Stem Cell Industry Leaders
Research & Analysis Methodologies
The publisher employs the following techniques for deriving its market research:
- Historical Databases: As the first and only market research firm to specialize in the stem cell industry, the publisher has 13+ years of historical data on each segment of the stem cell the industry. This provides an extremely rare and robust database for establishing market size determinations, as well as making future market predictions.
- Prolific Interviews with Industry Leaders: As the global leader in stem cell industry data, the publisher has interviewed hundreds of leaders from across the stem cell industry, including the CEO of FUJIFILM CDI, FUJIFILM Irvine Scientific, Pluristem Therapies, Celularity, and many others.
- Industry Relationships: The research team and its President/Founder, Cade Hildreth, Chair and present at a wide range of stem cell industry events, including Phacilitate's Advanced Therapies Week, World Stem Cell Summit (WSCS), Perinatal Stem Cell Society Congress, AABB's International Cord Blood Symposium (ICBS), and other events hosted within the U.S. and worldwide.
- Global Integrated Feedback: Because the publisher maintains the world's largest stem cell industry news site that is read by nearly a million unique readers per year and the company has large social media audiences (25.7K+ followers on Linked, 21.2K+ followers on Twitter, and 4.3K+ followers on Facebook), the publisher is able to publish content relevant to the industry and receive immediate feedback/input from a global community of readers. In short, the publisher's data is crowd-sourced from market participants worldwide, including those in diverse geographic regions.
- Preliminary Research: In addition to the interviews described above, the publisher conducts market surveys, executes social media polls, and aggregates market data from stem cell industry announcements, press releases, and corporate filings/presentations.
- Secondary Research: The publisher summarizes, collects and synthesizes existing market research that is relevant to the market area of interest.
- Future Projections: Using the resources described above, the publisher is uniquely positioned to make future projections about market size, market growth by segment, market trends, technology evolution, funding activities (financing rounds, M&A, and IPOs), and importantly, market leadership (market share by company).